Abstract
Erythropoiesis-stimulating agents (ESAs) remain first-choice to treat symptomatic anemia and delay transfusion dependence in most patients with lower-risk myelodysplastic syndromes (MDS) without del(5q). Deferasirox increased erythroid responses in some lower-risk MDS patients in clinical trials, and adding low-dose deferasirox to ESA treatment may further improve erythroid response. KALLISTO (NCT01868477) was a randomized, open-label, multicenter, phase II study. Lower-risk MDS patients received deferasirox at 10 mg/kg/d (dispersible tablets) or 7 mg/kg/d (film-coated tablets) plus erythropoietin (n = 11), or erythropoietin alone (n = 12) for 24 weeks. The primary endpoint was the between-group difference in erythroid response within 12 weeks. Erythroid response occurred in 27.3% of patients receiving deferasirox plus erythropoietin vs 41.7% of patients receiving erythropoietin alone within 12 weeks (difference 14.4%; 95% CI -24.0, 48.16). Within 24 weeks, the hematologic response rate was 27.3% with deferasirox plus erythropoietin vs 50% with erythropoietin alone, and hematologic improvement rates were 45.5% vs 100%. Deferasirox plus erythropoietin was generally well tolerated. In this small pilot study, combining low-dose de...Continue Reading
References
Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Jan 28, 2006·Mayo Clinic Proceedings·David P Steensma, John M Bennett
Apr 13, 2006·Blood·Bruce D ChesonHagop Kantarjian
Mar 21, 2008·Annals of Hematology·Victor MoyoSuneel Mundle
Oct 17, 2008·Experimental Hematology·Steve ElliottIain C Macdougall
Sep 22, 2009·British Journal of Haematology·Giuliana ZanninelliZvi I Cabantchik
May 11, 2010·Leukemia Research·Norbert GattermannUNKNOWN EPIC study investigators
Mar 16, 2012·Haematologica·Norbert GattermannChristian Rose
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan F ListEmmanuel Besa
Jun 29, 2012·Blood·Peter L GreenbergDetlef Haase
Mar 4, 2014·European Journal of Haematology·Emanuele AngelucciSante Tura
Mar 7, 2014·Leukemia Research·Rui CuiZhijian Xiao
May 10, 2017·Leukemia & Lymphoma·Emanuela MessaDaniela Cilloni
Jul 6, 2017·British Journal of Haematology·Heather A LeitchRena Buckstein
Dec 30, 2017·Oncotarget·Mathieu MeunierSophie Park
Citations
Jun 2, 2020·Expert Review of Anticancer Therapy·Jonathan FeldShyamala C Navada
Jul 30, 2019·Expert Review of Hematology·Ulrich GermingNorbert Gattermann
May 15, 2021·Leukemia Research·Kathrin NachtkampUlrich Germing